Marinus Pharmaceuticals, Inc. (MRNS) Q4 2022 Earnings Call Transcript

Marinus Pharmaceuticals, Inc. (MRNS) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET

Company Participants

Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations
Scott Braunstein - Chairman and Chief Executive Officer
Christy Shafer - Chief Commercial Officer
Joe Hulihan - Chief Medical Officer
Steve Pfanstiel - Chief Financial Officer and Chief Operating Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets
Joon Lee - Truist Securities
Rudy - SVB Securities
Andrew Tsai - Jefferies
Charles Duncan - Cantor Fitzgerald
Douglas Tsao - H.C. Wainwright
Jay Olson - Oppenheimer
Brian Skorney - Baird
Jason Butler - JMP Securities

Operator

Greetings everyone and welcome to the Marinus Pharmaceuticals’ Fourth Quarter and Full-Year 2022 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]

It is now my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. Please go ahead.

Sasha Damouni Ellis

Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.

I will now